Navepegritide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Navepegritide is a weekly shot that slowly releases C-type natriuretic peptide, or CNP. The FDA approved it in February 2026 for achondroplasia in children aged two and older.
Evidence grade for Navepegritide: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 2 human studies where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 human studies where nobody was given it
1 effects reported, 1 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Navepegritide is a weekly shot for children with achondroplasia, a genetic condition that limits bone growth. It is sold as Yuviwel. The FDA approved it in February 2026 for children aged two and older.
What people take it for
- Faster growth in children with achondroplasia.
- One shot a week.
What studies in people showed
In the main study, treated children grew 5.89 cm a year. Children on a dummy shot grew 4.41 cm. That is about one and a half centimetres more a year. The approval was based on how fast children grew. Nobody knows yet if they end up taller or healthier as adults. Follow-up studies are required.
What people report
Reports, not study results
The good
- In the study on this page, children grew about one and a half centimetres more a year.
The bad
- The study on this page does not list side effects, and we have not collected user reports on this one yet.
Where these come from: The good line is from the study and approval release on this page. We have not collected forum or user reports for this drug yet.
My bottom line
This is a drug for one condition, run by a specialist. It is not a height drug for healthy kids.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Navepegritide?
Navepegritide is a weekly shot that slowly releases C-type natriuretic peptide, or CNP. The FDA approved it in February 2026 for achondroplasia in children aged two and older.
Navepegritide slowly releases CNP from a carrier, so it needs only one shot a week. CNP pushes back against the overactive FGFR3 signal that causes achondroplasia, a genetic condition that limits bone growth. In the ApproaCH study, treated children grew 5.89 cm a year, against 4.41 cm on a dummy shot. The FDA gave it fast-track (accelerated) approval on February 27, 2026. It is the second CNP drug, after vosoritide.
How does Navepegritide work?
It is a slow-release form of CNP. It switches on the NPR-B receptor, which turns down the MAPK signal driven by FGFR3 in the growth plates of bones.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Not approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, by prescription in 0, not approved in 3. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- No single molecular weight: a CNP peptide conjugated to a PEG carrier of indefinite length (KEGG lists the peptide plus an indefinite PEG term)
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Navepegritide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026FDA approves once-weekly Yuviwel (navepegritide) for children with achondroplasia
This drug is approved and on the market. The FDA cleared once-weekly Yuviwel for children aged two and over with achondroplasia on 27 February 2026. It was an accelerated approval, which means the decision rested on how fast the children grew rather than on proof that they end up healthier adults. Confirmatory studies are required. It is the second drug of its kind, after vosoritide.
Accelerated approval February 27, 2026.
- Study in people2025Navepegritide in children with achondroplasia (ApproaCH)
Children grew faster on the weekly shot than on a dummy shot. Over a year, treated children gained about 5.9 cm against about 4.4 cm, a difference of roughly one and a half centimetres. Here is the limit. Growing faster for a year is not the same as ending up taller as an adult, or healthier, and that is what families want to know.
Growth velocity 5.89 versus 4.41 cm per year.
Where to buy Navepegritide
Navepegritide is an approved medicine. The approved product comes from a pharmacy, with a prescription. The vials below are sold “for research” and are not the approved drug.
No seller we track lists Navepegritide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Navepegritide been tested in people?
Not in a completed trial cited here. 2 human studies where nobody was given it. Navepegritide is a weekly shot that slowly releases C-type natriuretic peptide, or CNP. The FDA approved it in February 2026 for achondroplasia in children aged two and older.
What is the Navepegritide dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 2 human studies where nobody was given it
Is Navepegritide FDA-approved?
FDA-approved in 2026 for achondroplasia, the most common form of dwarfism. It was an early, conditional (accelerated) approval
Is navepegritide used for height in healthy children?
No. It is approved only for achondroplasia, a genetic condition that affects bone growth.